S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
New CBOE “special perk” helps traders target income every weekend (Ad)
How major US stock indexes fared Friday, 12/1/2023
US joins in other nations in swearing off coal power to clean the climate
New CBOE “special perk” helps traders target income every weekend (Ad)
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
New CBOE “special perk” helps traders target income every weekend (Ad)
How major US stock indexes fared Friday, 12/1/2023
US joins in other nations in swearing off coal power to clean the climate
New CBOE “special perk” helps traders target income every weekend (Ad)
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
New CBOE “special perk” helps traders target income every weekend (Ad)
How major US stock indexes fared Friday, 12/1/2023
US joins in other nations in swearing off coal power to clean the climate
New CBOE “special perk” helps traders target income every weekend (Ad)
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
New CBOE “special perk” helps traders target income every weekend (Ad)
How major US stock indexes fared Friday, 12/1/2023
US joins in other nations in swearing off coal power to clean the climate
New CBOE “special perk” helps traders target income every weekend (Ad)
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"

Tandem Diabetes Care Stock Price, News & Analysis (NASDAQ:TNDM)

$21.19
+0.95 (+4.69%)
(As of 12/1/2023 ET)
Compare
Today's Range
$18.45
$21.22
50-Day Range
$14.28
$21.99
52-Week Range
$13.82
$47.17
Volume
1.42 million shs
Average Volume
1.60 million shs
Market Capitalization
$1.38 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.50

Tandem Diabetes Care MarketRank™ Stock Analysis

Analyst Rating
Hold
2.29 Rating Score
Upside/​Downside
81.7% Upside
$38.50 Price Target
Short Interest
Healthy
12.25% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.64
Upright™ Environmental Score
News Sentiment
1.07mentions of Tandem Diabetes Care in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$241,544 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.56) to ($1.36) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.61 out of 5 stars

Medical Sector

118th out of 951 stocks

Surgical & Medical Instruments Industry

20th out of 94 stocks


TNDM stock logo

About Tandem Diabetes Care Stock (NASDAQ:TNDM)

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

TNDM Stock Price History

TNDM Stock News Headlines

All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
12 Best Diabetes Stocks To Buy Now
15 Stocks with Consistent Growth
Tandem Diabetes Care, Inc. (0M0F.L)
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Tandem Diabetes Care: More Ozempic Roadkill
Tandem Diabetes Care Inc TNDM
Tandem Diabetes hits 52-week low after guidance cut
See More Headlines
Receive TNDM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tandem Diabetes Care and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
12/02/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/28/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TNDM
Fax
N/A
Employees
2,600
Year Founded
2006

Price Target and Rating

Average Stock Price Target
$38.50
High Stock Price Target
$62.00
Low Stock Price Target
$21.00
Potential Upside/Downside
+81.7%
Consensus Rating
Hold
Rating Score (0-4)
2.29
Research Coverage
14 Analysts

Profitability

Net Income
$-94,590,000.00
Pretax Margin
-26.58%

Debt

Sales & Book Value

Annual Sales
$801.22 million
Book Value
$4.82 per share

Miscellaneous

Free Float
63,580,000
Market Cap
$1.38 billion
Optionable
Optionable
Beta
0.98

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report














TNDM Stock Analysis - Frequently Asked Questions

Should I buy or sell Tandem Diabetes Care stock right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last twelve months. There are currently 1 sell rating, 8 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TNDM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TNDM, but not buy additional shares or sell existing shares.
View TNDM analyst ratings
or view top-rated stocks.

What is Tandem Diabetes Care's stock price target for 2024?

14 analysts have issued 12-month target prices for Tandem Diabetes Care's shares. Their TNDM share price targets range from $21.00 to $62.00. On average, they expect the company's share price to reach $38.50 in the next twelve months. This suggests a possible upside of 81.7% from the stock's current price.
View analysts price targets for TNDM
or view top-rated stocks among Wall Street analysts.

How have TNDM shares performed in 2023?

Tandem Diabetes Care's stock was trading at $44.95 at the beginning of the year. Since then, TNDM stock has decreased by 52.9% and is now trading at $21.19.
View the best growth stocks for 2023 here
.

When is Tandem Diabetes Care's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our TNDM earnings forecast
.

How were Tandem Diabetes Care's earnings last quarter?

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) released its quarterly earnings data on Wednesday, November, 1st. The medical device company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.03. The medical device company earned $185.62 million during the quarter, compared to analyst estimates of $193.33 million. Tandem Diabetes Care had a negative trailing twelve-month return on equity of 23.90% and a negative net margin of 27.02%.

When did Tandem Diabetes Care's stock split?

Tandem Diabetes Care shares reverse split before market open on Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is John Sheridan's approval rating as Tandem Diabetes Care's CEO?

11 employees have rated Tandem Diabetes Care Chief Executive Officer John Sheridan on Glassdoor.com. John Sheridan has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Tandem Diabetes Care own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Block (SQ), Roku (ROKU), Lululemon Athletica (LULU) and PayPal (PYPL).

Who are Tandem Diabetes Care's major shareholders?

Tandem Diabetes Care's stock is owned by a variety of retail and institutional investors. Top institutional investors include Eminence Capital LP (8.42%), FMR LLC (4.59%), Paradice Investment Management LLC (2.34%), Jennison Associates LLC (1.73%), Chicago Capital LLC (1.39%) and Jacobs Levy Equity Management Inc. (1.22%). Insiders that own company stock include Brian B Hansen, Christopher J Twomey, Christopher J Twomey, David B Berger, Dick Allen, Elizabeth Anne Gasser, James Leal, John F Sheridan, Kathleen Mcgroddy-Goetz, Kim D Blickenstaff, Leigh Vosseller, Mark Reinstra, Rebecca B Robertson, Rebecca B Robertson, Shannon Marie Hansen and Susan Morrison.
View institutional ownership trends
.

How do I buy shares of Tandem Diabetes Care?

Shares of TNDM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:TNDM) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -